Nov 16, 2023 / 10:00AM GMT
Akash Tewari - Jefferies LLC, Research Division - Equity Analyst
All right. Good morning. Day 3 of our London Healthcare Conference. It has been a blast to see everyone here. I really do appreciate it.
Joining us -- my name is Akash Tewari. I'm a pharma and biotech analyst here at Jefferies. Joining me today is Merck, which is our topic in large-cap pharma. And joining us is Caroline Litchfield and Peter Dannenbaum, Head of IR. Caroline is CFO. Really, really appreciate the time. And Caroline told me she flew over just staying out with all of us today. So really appreciate that.
Maybe I can hand it to you for some brief introductory remarks, and then we can get into questions.
Caroline Litchfield - Merck & Co., Inc. - Executive VP & CFO
Yes. So first, can you hear me okay? First, thank you for having us, and thanks all for joining for this fireside chat. It's a really special time at Merck. As a company, we've got great momentum in our business. We're driving significant patient and customer impact across oncology, across vaccines,
Merck & Co Inc at Jefferies London Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers